期刊文献+

聚乙二醇定点修饰蛋白质药物的技术和临床研究进展 被引量:1

The Technique and Clinical Development of Site-specific PEGylated Protein Drugs
原文传递
导出
摘要 聚乙二醇(PEG)定点修饰蛋白药物是针对蛋白特定基团特定位点的修饰,相比于非定点随机修饰的特点是PEG修饰位点的单一与确定,避免了修饰异构体的干扰,能较好的保留药物体内外活性;修饰产物组成均一、性质稳定,便于质量控制,降低由修饰异构体引起的潜在的安全性风险,并很大程度上提高得率,降低成本。已有PEG定点修饰蛋白药物上市,还有部分处于临床试验阶段。本文综述了PEG定点修饰蛋白药物的技术研究与临床进展,包括PEG定点修饰剂、定点修饰方法、PEG定点修饰的上市和临床药物及面临的问题,并展望了PEG修饰技术未来的发展前景。 Site-specific polyethylene glycol (PEG) modification is the PEGylation of specific site of the protein. Compared with non-specific PEGylation, the advantages of site-specific PEGylation are the uniqueness of PEGylated site, no interference of modified isomers, preserved activity in vitro and in vivo; the modified product is homogeneous, stable, and convenient for quality control, and can reduce side effects of modified isomers, increase production yield and decrease costs. Site-specific PEGylation protein drugs are already on the market, others are still in clinical trials. This paper reviews the research progress of technique and clinical development of site-specific PEGylated protein drugs, including typical site-specific PEG modifiers, general methods of site-specific PEGylation, site-specific PEGylated drugs on the market and in clinical development, and problems faced with by researchers, and looks into the future development of site-specific PEG modification technique.
出处 《现代生物医学进展》 CAS 2015年第32期6381-6385,6301,共6页 Progress in Modern Biomedicine
基金 北京市科技计划项目(D08080200290808)
关键词 聚乙二醇定点修饰 定点修饰技术 PEG修饰药物 临床进展 Site-specific PEGylation Techinique of site-specific PEGylation PEGylated drugs Clinical development
  • 相关文献

参考文献27

  • 1Zbang Chun, Yang Xiao-lan, Yuan Yong-hua, et al. Site-Specific PEGylation of Therapeutic Proteins via Optimization of Both Accessible Reactive Amino Acid Residues and PEG Derivatives [J]. Biodrugs, 2012, 26(4): 209-215. 被引量:1
  • 2Vugmeyster Y, Entrican CA, Joyce AP, et al. Pharmacokinetic, Biodistribution and Biophysical Profiles of TNF Nanobodies Conjugated to Linear or Branched Poly (ethylene glycol)[J]. Bioconjugate Chem, 2012, 23(7): 1452-1462. 被引量:1
  • 3Kunstelj M, Fidler K, Skrajnar S, et al. Cysteine-Specific PEGylation ofrhG-CSF via Selenylsulfide Bond[J]. Bioconjugate Chem, 2013, 24 (6): 889-896. 被引量:1
  • 4Zhang Fan, Liu Mu-rong, Wan Hai-tong, et al. Discussion about several potential drawbacks of PEGylated therapeutic pro teins [J]. Biological and Pharmaceutical Bulletin, 2014, 37(3): 335-339. 被引量:1
  • 5Ryan SM, Wang X, Mantovani G, et al. Conjugation of salmoncalcitonin to a combed-shaped end functionalized poly(poly(cthylene glycol) methyl ether methacrylate) yields a bioactive stable conjugate [J]. Journal of Controlled Release, 2009, 135(1): 51-59. 被引量:1
  • 6Hu Jun-li, Walter S. N-terminal specificity of PEGylation of human bone morphogenetic protein-2 at acidic pH[J]. International Journal of Pharmaceutics, 2011,413(1-2): 140-146. 被引量:1
  • 7Gao Ming-ming, Tian Hong, Ma Chen, et al. Expression, purification and C-terminal site-specific PEGylation of cysteine-mutated glucagon-like peptide-1 [J]. Appl Biochem Biotechnol, 2010, 162(1): 155-165. 被引量:1
  • 8Thorn J, Anderson D, McGregor J, et al. Recombinant protein hydrazides: application to site-specific protein PEGylation [J]. Bioconjug Chem, 2011, 22(6): 1017-1020. 被引量:1
  • 9Neumann H, Wang K, Davis L, et al. Encoding multiple unnatural amino acids via evolution of a quadruplet-decoding ribosome [J]. Nature, 2010, 464(7287): 441-444. 被引量:1
  • 10Voloshchuk N, Montclare JK. Incorporation of unnatural amino acids for synthetic biology[J]. Mol Biosyst, 2010, 6(1): 65-80. 被引量:1

二级参考文献14

  • 1牛晓霞,刘金毅,杨轶,吴晓东.集成干扰素突变体Ⅱ的分子构建、表达及提纯[J].中国生物工程杂志,2006,26(12):1-5. 被引量:4
  • 2Sims G E, Snape T J. A method for the estimation of polyethylene glycol in plasma protein fractions. Anal Biochem, 1980, 107:60-63 被引量:1
  • 3中国药典委员会编.中华人民共和国药典.2005版三部.北京:化学工业出版社,2005.附录56-57 被引量:1
  • 4Lai L, Hui C K, Leung N, et al. Pegylated interferon alpha-2a (40 kDa ) in the treatment of chronic hepatitis B. Int J Nanomedicine, 2006, 1 (3) :255 -262 被引量:1
  • 5Shiffman M L, Suter F, Bacon B R, et al. Peginterferon alfa- 2a and ribavifin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med, 2007, 357(2) :124-134 被引量:1
  • 6George S, Hutson T E, Mekhail T, et al. Phase I trial of PEG- interferon and recombinant IL-2 in patients with metastatic renal cell carcinoma. Cancer Chemother Pharmacol, 2007,30 ( 8 ) : 839-846 被引量:1
  • 7Doherty D H, Rosendahl M S, Smith D J, et al. Site-speclfic PEGylation of engineered cysteine analogues of recombinant human granulocyte-macrophage colony-stimulating factor. Bioconjug Chem, 2005, 16(5) : 1291 - 1298 被引量:1
  • 8Balan S, Choi J W, Godwin A, et al. Site-specific PEGylafion of protein disulfide bonds using a three-carbon bridge. Bioconjug Chem, 2007, 18 ( 1 ) :61-76 被引量:1
  • 9Brocchini S, Godwin A, Balan S, et al. Disulfide bridge based PEGylation of proteins. Nat Protoc, 2006,1 (5) :2241 - 2252 被引量:1
  • 10Hu R, Bekisz J, Schmeisser H, et al. Human IFN-α protein engineering: The amino acid residues at position 86 and 90 are important for antiproliferative activity. The Journal of Immunology, 2001, 167:1482 - 1489 被引量:1

共引文献4

同被引文献9

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部